Wall Street analysts expect Pluristem Therapeutics Inc. (NASDAQ:PSTI) to report earnings per share of ($0.08) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Pluristem Therapeutics’ earnings. Pluristem Therapeutics also reported earnings of ($0.08) per share in the same quarter last year. The business is scheduled to issue its next earnings results on Wednesday, March 14th.
On average, analysts expect that Pluristem Therapeutics will report full year earnings of ($0.34) per share for the current year. Zacks’ EPS averages are a mean average based on a survey of research firms that cover Pluristem Therapeutics.
Several equities research analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Pluristem Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd. Maxim Group set a $3.00 price objective on shares of Pluristem Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, February 21st. HC Wainwright set a $4.00 price objective on shares of Pluristem Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, January 16th. Finally, ValuEngine downgraded shares of Pluristem Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, December 20th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. Pluristem Therapeutics has a consensus rating of “Hold” and a consensus price target of $4.00.
Shares of Pluristem Therapeutics (PSTI) traded down $0.03 during mid-day trading on Wednesday, reaching $1.48. 211,176 shares of the company traded hands, compared to its average volume of 286,724. Pluristem Therapeutics has a 1 year low of $1.06 and a 1 year high of $2.12. The firm has a market capitalization of $162.94, a price-to-earnings ratio of -4.77 and a beta of 0.21.
TRADEMARK VIOLATION NOTICE: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/03/14/pluristem-therapeutics-inc-psti-expected-to-announce-earnings-of-0-08-per-share.html.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.